The U.S. Food and Drug Administration (FDA) has taken significant action against three companies — Bailey’s Wellness, Holista, and House of Alchemy — by issuing warning letters for the sale of unapproved cannabidiol (CBD) products intended for pets.
Concerns about residues in food-producing animals
The FDA’s primary focus is the implications of using CBD products in food-producing animals. The agency expressed concerns regarding potential risks not only to animal health but also to human food safety. Data on the formation of residues in animal products — such as meat, milk, and eggs — resulting from the consumption of CBD by food-producing animals is currently insufficient. This lack of information concerns FDA about the safety of these food products for human consumers.
In the warning letters, the FDA has mandated that these companies respond within 15 working days to outline how they intend to remedy these violations and prevent future occurrences. Failure to comply may lead to severe consequences, including the confiscation of products.
Cannabis in veterinary practice report
The American Veterinary Medical Association (AVMA) has proactively updated its report, Cannabis in Veterinary Medicine, which serves as a resource for practitioners navigating the complexities of cannabis regulation and research.
Veterinary professionals are encouraged to engage with the AVMA’s resources to stay abreast of the latest developments in this field.
